R
Ryan Gierke
Researcher at Centers for Disease Control and Prevention
Publications - 25
Citations - 5081
Ryan Gierke is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Pneumococcal conjugate vaccine & Medicine. The author has an hindex of 12, co-authored 21 publications receiving 3838 citations. Previous affiliations of Ryan Gierke include United States Department of Health and Human Services.
Papers
More filters
Journal ArticleDOI
Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020
Stephanie R. Bialek,Ellen O. Boundy,Virginia B. Bowen,Nancy A. Chow,Amanda C. Cohn,Nicole F. Dowling,Sascha R. Ellington,Ryan Gierke,Aron J. Hall,Jessica R. MacNeil,Priti Patel,Georgina Peacock,Tamara Pilishvili,Hilda Razzaghi,Nia Reed,Matthew D. Ritchey,Erin K. Sauber-Schatz +16 more
TL;DR: COVID-19 cases in the United States that occurred during February 12-March 16, 2020 and severity of disease (hospitalization, admission to intensive care unit [ICU], and death) were analyzed by age group, suggesting that the risk for serious disease and death from CO VID-19 is higher in older age groups.
Journal ArticleDOI
Coronavirus Disease 2019 in Children - United States, February 12-April 2, 2020.
Stephanie R. Bialek,Ryan Gierke,Michelle M Hughes,Lucy A McNamara,Tamara Pilishvili,Tami H. Skoff +5 more
TL;DR: Data support previous findings that children with COVID-19 might not have reported fever or cough as often as do adults and social distancing and everyday preventive behaviors remain important for all age groups as patients with less serious illness and those without symptoms likely play an important role in disease transmission.
Journal ArticleDOI
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices
Almea Matanock,Grace M. Lee,Ryan Gierke,Miwako Kobayashi,Andrew J. Leidner,Tamara Pilishvili +5 more
TL;DR: ACIP voted to remove the recommendation for routine PCV13 use among adults aged ≥65 years and to recommend administration ofPCV13 based on shared clinical decision-making for adults aged ≤65 years who do not have an immunocompromising condition,† cerebrospinal fluid (CSF) leak, or cochlear implant, and who have not previously received PCV 13.
Journal ArticleDOI
Geographic Differences in COVID-19 Cases, Deaths, and Incidence - United States, February 12-April 7, 2020.
Cdc Covid Response Team,Stephanie R. Bialek,Virginia B. Bowen,Nancy A. Chow,Aaron T. Curns,Ryan Gierke,Aron J. Hall,Michelle M Hughes,Tamara Pilishvili,Matthew D. Ritchey,Katherine Roguski,Benjamin Silk,Tami H. Skoff,Preethi Sundararaman,Emily N. Ussery,Michael Vasser,Hilary K. Whitham,John Wen +17 more
TL;DR: The geographic distribution of laboratory-confirmed COVID-19 cases and related deaths reported by each U.S. state, each territory and freely associated state,* DC, and NYC during February 12-April 7, 2020, and estimates cumulative incidence for each jurisdiction are described.
Journal ArticleDOI
Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Miwako Kobayashi,Nancy M. Bennett,Ryan Gierke,Olivia Almendares,Matthew R. Moore,Cynthia G. Whitney,Tamara Pilishvili +6 more
TL;DR: The recommended intervals between PCV13 and PPSV23 given in series differ by age and risk group and the order in which the two Vaccine Advisory Committee on Immunization Practices (ACIP) currently recommends.